The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal

Journal of Gastrointestinal Oncology

Volumn 3, Issue 2, 2012, Pages 105-119

  Ballehaninna, Umashankar K ^a,b   Chamberlain, Ronald S ^b,c,d  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b SAINT BARNABAS MEDICAL CENTER   (United States)

^c University of Medicine and Dentistry of New Jersey   (United States)

^d ST GEORGE S UNIVERSITY SCHOOL OF MEDICINE   (Grenada)

Author keywords

Ca 19 9; Diagnosis; Pancreatic cancer; Prognosis; Recurrence; Resectability; Screening; Tumor markers

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN;

ANTIGEN FUNCTION; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; EVIDENCE BASED PRACTICE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; METASTASIS; OBSTRUCTIVE JAUNDICE; PANCREAS ADENOCARCINOMA; PHENOTYPE; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT FAILURE;

EID: 84995748195     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2011.021     Document Type: Article

References (82)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60, 277-300.
2. Ellison LF, Wilkins K. An update on cancer survival. Health Rep 2010, 21, 55-60.
3. Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer, an update. Dig Dis 2010, 28, 645-56.
4. Li J, Merl MY, Chabot J, Saif MW. Updates of adjuvant therapy in pancreatic cancer, where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP 2010, 11, 310-2.
5. Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009, 6, e1000046.
6. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979, 5, 957-71.
7. Kannagi R. Carbohydrate antigen sialyl Lewis a-its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J 2007, 30, 189-209.
8. Safi F, Roscher R, Bittner R, Schenk luhn B, Dopfer HP, Beger HG. High sensitiv it y and specif icit y of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas 1987, 2, 398-403.
9. Duraker N, Hot S, Polat Y, Höbek A, Gençler N, Urhan N. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 2007, 95, 142-7.
10. Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int 2007, 6, 641-5.
11. Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jørgensen J, Wolf H, et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999, 45, 54-61.
12. Ritts RE, Pitt HA. CA 19-9 in pancreatic cancer. Surg Oncol Clin N Am 1998, 7, 93-101.
13. Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer, analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999, 94, 1941-6.
14. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007, 33, 266-70.
15. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer, a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010, 21, 441-7.
16. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990, 85, 350-5.
17. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004, 19, 182-6.
18. Satake K, Takeuchi T, Homma T, Ozaki H. CA19-9 as a screening and diagnostic tool in symptomatic patients, the Japanese experience. Pancreas 1994, 9, 703-6.
19. Chang CY, Huang SP, Chiu HM, Lee YC, Chen MF, Lin JT. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepatogastroenterology 2006, 53, 1-4.
20. Tessler DA, Catanzaro A, Velanovich V, Havstad S, Goel S. Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis. Am J Surg 2006, 191, 191-7.
21. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989, 110, 704-9.
22. Safi F, Schlosser W, Kolb G, Beger HG. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 1997, 1, 106-12.
23. Jiang XT, Tao HQ, Zou SC. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int 2004, 3, 464-8.
24. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, FernandezdelCastillo C, Warshaw AL. Per ioperat ive CA19-9 levels ca n predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006, 24, 2897-902.
25. Kim YC, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, et al. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? J Gastroenterol Hepatol 2009, 24, 1869-75.
26. Kondo N, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, et al. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2010, 17, 2321-9.
27. DeWitt J, Devereaux B, Chriswell M, McGreevy K, Howard T, Imperiale TF, et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 2004, 141, 753-63
28. Ritts RE Jr, Nagorney DM, Jacobsen DJ, Talbot RW, Zurawski VR Jr. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 1994, 9, 707-16.
29. Paganuzzi M, Onetto M, Marroni P, Barone D, Conio M, Aste H, et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988, 61, 2100-8.
30. Nakao A, Oshima K, Nomoto S, Takeda S, Kaneko T, Ichihara T, et al. Clinical usefulness of CA-19-9 in pancreatic carcinoma. Semin Surg Oncol 1998, 15, 15-22.
31. Kau SY, Shyr YM, Su CH, Wu CW, Lui WY. Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers. J Am Coll Surg 1999, 188, 415-20.
32. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003, 138, 951-5, discussion 955-6.
33. Kiliç M, Göçmen E, Tez M, Ertan T, Keskek M, Koç M. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006, 49, 241-4.
34. Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 2007, 14, 539-44.
35. Maithel SK, Maloney S, Winston C, Gönen M, D'Angelica MI, Dematteo RP, et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 2008, 15, 3512-20.
36. Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol 2008, 14, 3750-3.
37. Halloran CM, Ghaneh P, Connor S, Sutton R, Neoptolemos JP, Raraty MG. Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy. Br J Surg 2008, 95, 453-9.
38. Sperti C, Pasquali C, Catalini S, Cappellazzo F, Bonadimani B, Behboo R, et al. CA 19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol 1993, 52, 137-41.
39. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994, 69, 515-9.
40. Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 2001, 91, 490-5.
41. Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002, 32, 35-41.
42. Micke O, Bruns F, Schäfer U, Kurowski R, Horst E, Willich N. CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res 2003, 23, 835-40.
43. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP. Undetec table preoperat ive levels of serum CA 19-9 cor relate with improved sur v ival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 2004, 11, 644-9.
44. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer, the implication for clinical trials. Br J Cancer 2005, 93, 740-3.
45. Smith RA, Bosonnet L, Ghaneh P, Raraty M, Sutton R, Campbell F, et al. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg 2008, 25, 226-32.
46. Waraya M, Yamashita K, Katagiri H, Ishii K, Takahashi Y, Furuta K, et al. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol 2009, 16, 1231-40.
47. Turrini O, Schmidt CM, Moreno J, Parikh P, Matos JM, House MG, et al. Very high serum CA 19-9 levels, a contraindication to pancreaticoduodenectomy? J Gastrointest Surg 2009, 13, 1791-7.
48. Wasan HS, Springett GM, Chodkiewicz C, Wong R, Maurel J, Barone C, et al. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer 2009, 101, 1162-7.
49. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 2010, 17, 1794-801.
50. Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 1997, 4, 551-6.
51. Hernandez JM, Cowgill SM, Al-Saadi S, Collins A, Ross SB, Cooper J, et al. CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg 2009, 13, 349-53.
52. Nishida K, Kaneko T, Yoneda M, Nakagawa S, Ishikawa T, Yamane E, et al. Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J Surg Oncol 1999, 71, 140-6.
53. Ishii H, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 1997, 44, 279-83.
54. Gogas H, Lofts FJ, Evans TR, Daryanani S, Mansi JL. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer 1998, 77, 325-8.
55. Halm U, Schumann T, Schiefke I, Witzigmann H, Mössner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000, 82, 1013-6.
56. Stemmler J, Stieber P, Szymala AM, Schalhorn A, Schermuly MM, Wilkowski R, et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie 2003, 26, 462-7.
57. Ziske C, Schlie C, Gorschlüter M, Glasmacher A, Mey U, Strehl J, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003, 89, 1413-7.
58. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005, 93, 195-9.
59. Pohlank K, Hilbig A, Pelzer U, Stieler J, Roll L, Goerke A, et al. Decrease of CA 19-9 in patients with advanced pancreatic cancer (APC) undergoing chemotherapy predicts survival time[abstract]. J Clin Oncol 2008, S26, 15574.
60. Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Fugazza C, et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009, 115, 2630-9.
61. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008, 9, 132-8.
62. Fogelman DR, Pathak P, Qiao W, Chadha R, Jhamb J, Melisi D, et al. Serum CA 19-9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC)[abstract]. J Clin Oncol 2008, S26, 15514.
63. Haas M, Laubender RP, Stieber P, Holdenrieder S, Bruns CJ, Wilkowski R, et al. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol 2010, 31, 351-7.
64. Takahashi H, Ohigashi H, Ishikawa O, Eguchi H, Gotoh K, Yamada T, et al. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 2010, 251, 461-9.
65. Willett CG, Daly WJ, Warshaw AL. CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 1996, 172, 350-2.
66. Boeck S, Haas M, Laubender RP, Kullmann F, Klose C, Bruns CJ, et al. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res 2010, 16, 986-94.
67. Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 2007, 140, 31-5.
68. Decker GA, Batheja MJ, Collins JM, Silva AC, Mekeel KL, Moss AA, et al. Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (N Y) 2010, 6, 246-54.
69. Bedi MM, Gandhi MD, Jacob G, Lekha V, Venugopal A, Ramesh H. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis, is there any benefit? Indian J Gastroenterol 2009, 28, 24-7.
70. Ulla Rocha JL, Alvarez Sanchez MV, Paz Esquete J, Fernandez Salgado E, Alvarez Alvarez C, Vazquez Sanluis MJ, et al. Evaluation of the biliopancreatic region using endoscopic ultrasonography in patients referred with and without abdominal pain and CA 19-9 serum level elevation. JOP 2007, 8, 191-7.
71. Paganuzzi M, Onetto M, Marroni P, Barone D, Conio M, Aste H, et al. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases. Cancer 1988, 61, 2100-8.
72. Marcouizos G, Ignatiadou E, Papanikolaou GE, Ziogas D, Fatouros M. Highly elevated serum levels of CA 19-9 in choledocholithiasis, a case report. Cases J 2009, 2, 6662.
73. Kim HR, Lee CH, Kim YW, Han SK, Shim YS, Yim JJ. Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med 2009, 47, 750-4.
74. Ventrucci M, Pozzato P, Cipolla A, Uomo G. Persistent elevation of serum CA 19-9 with no evidence of malignant disease. Dig Liver Dis 2009, 41, 357-63.
75. Mery CM, Duarte-Rojo A, Paz-Pineda F, Gómez E, Robles-Díaz G. Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer? Rev Invest Clin 2001, 53, 511-7.
76. Ong SL, Sachdeva A, Garcea G, Gravante G, Metcalfe MS, Lloyd DM, et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci 2008, 53, 3213-7.
77. Basso D, Fabris C, Plebani M, Del Favero G, Muraca M, Vilei MT, et al. Alterations in bilirubin metabolism during extra- and intrahepatic cholestasis. Clin Investig 1992, 70, 49-54.
78. Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, et al. CA19-9 serum levels in obstructive jaundice, clinical value in benign and malignant conditions. Am J Surg 2009, 198, 333-9.
79. Ortiz-González J, Alvarez-Aguila NP, Medina-Castro JM. Adjusted carbohydrate antigen 19-9. Correlation with histological grade in pancreatic adenocarcinoma. Anticancer Res 2005, 25, 3625-7.
80. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, et al. Serum markers in patients with resectable pancreatic adenocarcinoma, macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006, 12, 442-6.
81. Eguchi H, Ishikawa O, Ohigashi H, Takahashi H, Yano M, Nishiyama K, et al. Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer. Pancreas 2009, 38, 791-8.
82. Grote T, Logsdon CD. Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol 2007, 23, 508-14.